Inside the research

Merck & Co., Inc.

MRK Research profile · latest available data

Price overview

$148.78

▲ +0.80 (+0.5%)

52w hi$155.53
52w lo$75.39
Vol8.29M
As of25 Sep 2026

The Verdict

Hold

Our score +0.26

Short+0.27
Medium+0.36
Long+0.05

computed 2026-09-27

Key fundamentals

Merck & Co., Inc.

Healthcare · Drug Manufacturers - General

Market cap$367.07B
Enterprise value$413.89B
Trailing P/E119.02x
Forward P/E15.61x
EV / EBITDA14.34x
P / S (ttm)5.51x
Profit margin4.8%
Return on equity7.0%
Revenue growth+5.1%
Debt / equity128.41

Layer Breakdown

LayerRawContribution
Fundamental+0.12
Sector+0.08
Technical+0.20
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

United States · www.merck.com

Risk Metrics

Beta vs SPX0.31
Corr SPX0.17
Annual vol29.0%
Annual ret+16.1%
Sharpe0.56
Max DD-36.5%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$129.74
High / Low$150.00 / $100.00
Median$135.00
Analysts27
Strong Buy4
Buy15
Hold10
Sell0
Strong Sell0

Recent rating actions

2026-05-01Wells Fargo→ Overweight
2026-04-13UBS→ Buy
2026-04-06JP Morgan→ Overweight
2026-03-30RBC Capital→ Outperform
2026-03-20Citigroup→ Neutral
2026-03-12Wells Fargo→ Overweight

Material Events

DateEvent8-K
2026-08-04Earnings Release, Exhibitsread
2026-05-28Shareholder Voteread
2026-05-22Other Material Event, Exhibitsread
2026-04-30Earnings Release, Exhibitsread
2026-02-03Earnings Release, Exhibitsread
2025-12-04Other Material Event, Exhibitsread
2025-10-30Earnings Release, Exhibitsread
2025-09-09Other Material Event, Exhibitsread
2025-07-29Earnings Release, Restructuring…read
2025-05-29Shareholder Voteread
2025-04-24Earnings Release, Exhibitsread
2025-02-04Earnings Release, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-13Guindo ChirfiEVP, Access, Policy & ComSell10.00K$1.35M
2026-08-12Zachary JenniferEVP, General CounselSell80.31K$10.72M
2026-08-12DeLuca Richard R.EVP&Pres, Merck Animal HeSell11.10K$1.46M
2026-08-12Zachary JenniferEVP, General CounselOption exercise13.43K$1.14M
2026-08-12DeLuca Richard R.EVP&Pres, Merck Animal HeSell600$79.22K
2026-08-12Zachary JenniferEVP, General CounselOption exercise41.49K$4.89M
2026-08-11DeLuca Richard R.EVP&Pres, Merck Animal HeSell5.43K$718.26K
2026-08-11DeLuca Richard R.EVP&Pres, Merck Animal HeSell7.41K$973.16K
2026-08-10DeLuca Richard R.EVP&Pres, Merck Animal HeSell20.78K$2.71M
2026-08-06DeLuca Richard R.EVP&Pres, Merck Animal HeSell805$105.47K

Flow & Concentration

Insider 180d net-$29.98M
Insider buys / sells0 / 17
Insider biasSellers
13F holders8
Top-5 share98.9%
HHI4,245 (concentrated)

Top Holders

HolderValueShares
State Street Corp$15.57B120.41M
Fidelity / FMR LLC$5.84B45.44M
Capital Research / Capital World$1.90B14.79M
Citadel Advisors$1.18B9.18M
AQR Capital Management$1.04B8.13M
Millennium Management$271.70M2.11M
Bridgewater Associates$3.89M30.25K
T. Rowe Price Group$2.38M18.52M

As of 2026-06-30

Dividends

Yield (TTM)1.14%
$ / share (TTM)$1.70
5y CAGR+6.7%

Annual dividend per share

2021$2.61
2022$2.80
2023$2.96
2024$3.12
2025$3.28
2026$0.85

SEC Filings

DateFormDoc
2026-08-134view
2026-08-134view
2026-08-124view
2026-08-104view
2026-08-074view
2026-08-0710-Qview
2026-08-074view
2026-08-0713F-HRview
2026-08-074view
2026-08-048-Kview
2026-07-014view
2026-07-014view
2026-07-014view
2026-06-2411-Kview
2026-06-2411-Kview

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$60.12B+5.9%
Net income$18.25B+2.2%
Cash from ops$16.47B+12.9%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$148.06$149.98$147.48$148.788.29M
Sep 24$148.17$151.46$147.90$147.9810.31M
Sep 23$151.32$152.01$146.89$148.089.70M
Sep 22$148.69$153.57$148.04$150.9111.17M
Sep 21$146.79$150.49$145.60$149.507.99M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →